seizure treatment

A Rare-Disease Approach to Seizure Treatment

As rates of epilepsy continue to climb, drug developers have cut back in research in this area, many are deterred by the large number of existing drugs and off-patent drugs on the market, the challenge of large clinical trials and unclear financial rewards.


University-Generated IP

Effective Strategy and Partnering Approaches For University-Generated IP

This white paper explores the issue of the “have” versus “have-nots” in the academic-industry partnering landscape and offers specific solutions to increase productivity and investment returns. With valuable insight from our peers at Vantage Partners, we look at data that point to the top one percent of research universities absorbing most of the revenue from commercialization of university-generated IP – and what can be done about it.

Download the white paper

Immunotherapies white paper

Back Bay Report on Neoantigen-Based Cancer Immunotherapy

By Jonathan P. Gertler, MD

Immuno-oncology, a promise for decades, has burst forth as a clear means to advance patient care and spur research and development. Science and industry are working fervently to untangle this data-heavy, rapidly-evolving field and bring effective IO combinations to more patients. As positive data and widespread support accumulate for the potential checkpoint inhibitors and neoantigens in numerous challenging and refractory cancers, hundreds of trials are being implemented that seek to increase efficacy and bring these novel therapeutics to more patients in critical need.


Transcatheter Mitral Valve Technologies: The Heart of Cardiovascular Device Innovation

Transcatheter Mitral Valve Technologies: The Heart of Cardiovascular Device Innovation

By Tejdeep Singh Bawa, Michelle Hoffmann, Susan Thompson, Stephanie Kwei

Medical device companies developing next-generation mitral valve repair and replacement technologies have generated unprecedentedly high valuations at ever-earlier stages of device development. Medtech investors are acquiring early-stage transcatheter mitral valve technologies long before commercialization and even before critical clinical data is amassed.


Back Bay insights on US Biosimilars 2018

US Biosimilars 2018: Opportunities and Challenges

RE: Jonathan P. Gertler

As we start a new year, we would like to share Back Bay’s latest thought piece, US Biosimilars: Opportunities and Challenges.  Researched and written by Michelle Hoffmann, PhD and Jon Barry, MD, the insights are substantive, with calculated optimism.

Read the Whitepaper